|
Orthologous residues
|
|
4E‑BP1 (human): S112‑p, 4E‑BP1 (mouse): S111‑p, 4E‑BP1 (rat): S111‑p, 4E‑BP1 (fruit fly): ‑
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), GM0637 (fibroblast), GM9607 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ATM (human)
|
transfection of inactive enzyme, modification site within consensus motif, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, phosphopeptide analysis, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
rapamycin
|
insulin
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
eIF4E (human)
|
|
Disrupts
|
|
|
co-immunoprecipitation
|
|